

1. Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010;19:1893–1907.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. *CA Cancer J Clin* 2010;60:277–300.
3. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. *N Engl J Med* 2000;343:162–168.
4. Davis DM, Marcet JE, Fratinni JC, et al. Is it time to lower the recommended screening age for colorectal cancer? *J Am Coll Surg* 2011;213:352–361.
5. Lee PY, Fletcher WS, Sullivan ES, et al. Colorectal cancer in young patients: characteristics and outcome. *Am Surg* 1994;60:607–612.
6. Brown MO, Lanier AP, Becker TM. Colorectal cancer incidence and survival among Alaska Natives, 1969–1993. *Int J Epidemiol* 1998;27:388–396.
7. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. *CA Cancer J Clin* 1999;49:33–64, 1.
8. Nelson RL, Persky V, Turyk M. Determination of factors responsible for the declining incidence of colorectal cancer. *Dis Colon Rectum* 1999;42:741–752.
9. Staszewski J, Haenszel W. Cancer mortality among the Polish-born in the United States. *J Natl Cancer Inst* 1965;35:291–297.
10. Whittemore AS, Wu-Williams AH, Lee M, et al. Diet, physical activity, and colorectal cancer among Chinese in North America and China. *J Natl Cancer Inst* 1990;82:915–926.
11. McMichael AJ, Giles GG. Cancer in migrants to Australia: extending the descriptive epidemiological data. *Cancer Res* 1988;48:751–756.
12. Kune S, Kune GA, Watson L. The Melbourne colorectal cancer study: incidence findings by age, sex, site, migrants and religion. *Int J Epidemiol* 1986;15:483–493.
13. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. *Nat Genet* 1997;17:79–83.
14. Rozen P, Shomrat R, Strul H, et al. Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. *Gastroenterology* 1999;116:54–57.
15. Weber TK, Chin HM, Rodriguez-Bigas M, et al. Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer. *JAMA* 1999;281:2316–2320.
16. Nelson RL, Persky V, Turyk M. Time trends in distal colorectal cancer subsite location related to age and how it affects choice of screening modality. *J Surg Oncol* 1998;69:235–238.
17. Nelson RL, Dollear T, Freels S, et al. The relation of age, race, and gender to the subsite location of colorectal carcinoma. *Cancer* 1997;80:193–197.
18. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. *J Natl Cancer Inst* 2011;103:1498–1506.
19. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1998. *CA Cancer J Clin* 1998;48:6–29.
20. Wilmink AB. Overview of the epidemiology of colorectal cancer. *Dis Colon Rectum* 1997;40:483–493.
21. Obrand DL, Gordon PH. Continued change in the distribution of colorectal carcinoma. *Br J Surg* 1998;85:246–248.
22. Kempainen M, Raiha I, Sourander L. A marked increase in the incidence of colorectal cancer over two decades in southwest Finland. *J Clin Epidemiol* 1997;50:147–151.
23. Ji BT, Devesa SS, Chow WH, et al. Colorectal cancer incidence trends by subsite in urban Shanghai, 1972–1994. *Cancer Epidemiol Biomarkers Prev* 1998;7:661–666.
24. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. *Cancer Res* 1998;58:1713–1718.
25. Fink D, Nebel S, Norris PS, et al. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. *Br J Cancer* 1998;77:703–708.
26. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. *Cancer Res* 1998;58:5473–5477.
27. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. *N Engl J Med* 1994;331:1669–1674.
28. Pariente A, Milan C, Lafon J, et al. Colonoscopic screening in first-degree relatives of patients with ‘sporadic’ colorectal cancer: a case-control study. The Association Nationale des Gastroenterologues des Hopitaux and Registre Bourguignon des Cancers Digestifs (INSERM CRI 9505). *Gastroenterology* 1998;115:7–12.
29. Guillem JG, Forde KA, Treat MR, et al. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. *Dis Colon Rectum* 1992;35:523–529.
30. Winawer SJ, Zauber AG, Gerdes H, et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. *N Engl J Med* 1996;334:82–87.
31. Ponz de Leon M, Scapoli C, Zanghieri G, et al. Genetic transmission of colorectal cancer: exploratory data analysis from a population based registry. *J Med Genet* 1992;29:531–538.
32. Harris MJ, Coggan M, Langton L, et al. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. *Pharmacogenetics* 1998;8:27–31.
33. Welfare M, Monesola Adeokun A, Bassendine MF, et al. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 1999;8:289–292.
34. Chen J, Giovannucci E, Hankinson SE, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. *Cancer Res* 1996;56:4862–4864.
35. Butler LM, Millikan RC, Sinha R, et al. Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study. *Mutat Res* 2008;638:162–174.
36. Hartz A, He T, Ross JJ. Risk factors for colon cancer in 150,912 postmenopausal women. *Cancer Causes Control* 2012;23:1599–1605.
37. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. *Am J Epidemiol* 1998;148:761–774.
38. Slatery ML, Potter J, Caan B, et al. Energy balance and colon cancer—beyond physical activity. *Cancer Res* 1997;57:75–80.
39. Renehan AG, Flood A, Adams KF, et al. Body mass index at different adult ages, weight change, and colorectal cancer risk in the National Institutes of Health-AARP Cohort. *Am J Epidemiol* 2012;176:1130–1140.
40. Potter JD. Colorectal cancer: molecules and populations. *J Natl Cancer Inst* 1999;91:916–932.
41. Willett WC, Stampfer MJ, Colditz GA, et al. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. *N Engl J Med* 1990;323:1664–1672.
42. Key TJ, Fraser GE, Thorogood M, et al. Mortality in vegetarians and non-vegetarians: detailed findings from a collaborative analysis of 5 prospective studies. *Am J Clin Nutr* 1999;70:516S–524S.
43. Probst-Hensch NM, Sinha R, Longnecker MP, et al. Meat preparation and colorectal adenomas in a large sigmoidoscopy-based case-control study in California (United States). *Cancer Causes Control* 1997;8:175–183.
44. Parr CL, Hjartaker A, Lund E, et al. Meat intake, cooking methods and risk of proximal colon, distal colon and rectal cancer: the Norwegian Women and Cancer (NOWAC) cohort study. *Int J Cancer* 2013;133:1153–1163.
45. Egeberg R, Olsen A, Christensen J, et al. Associations between red meat and risks for colon and rectal cancer depend on the type of red meat consumed. *J Nutr* 2013;143:464–472.
46. McCullough ML, Gapstur SM, Shah R, et al. Association between red and processed meat intake and mortality among colorectal cancer survivors. *J Clin Oncol* 2013;31:2773–2782.
47. Li G, Ma D, Xiang Y, et al. Coffee consumption and risk of colorectal cancer: a meta-analysis of observational studies. *Public Health Nutr* 2013;16:346–357.
48. Sinha R, Cross AJ, Daniel CR, et al. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. *Am J Clin Nutr* 2012;96:374–381.
49. Burkitt DP. Epidemiology of cancer of the colon and rectum. 1971. *Dis Colon Rectum* 1993;36:1071–1082.
50. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. *J Natl Cancer Inst* 1992;84:1887–1896.
51. Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European prospective investigation into cancer and nutrition (EPIC). *PLoS One* 2012;7:e39361.
52. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. *N Engl J Med* 1999;340:169–176.
53. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. *N Engl J Med* 2000;342:1149–1155.
54. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. *N Engl J Med* 2000;342:1156–1162.
55. Wargovich MJ. New dietary anticarcinogens and prevention of gastrointestinal cancer. *Dis Colon Rectum* 1988;31:72–75.
56. Bamia C, Lajiou P, Buckland G, et al. Mediterranean diet and colorectal cancer risk: results from a European cohort. *Eur J Epidemiol* 2013;28:317–328.
57. Bostick RM, Fosdick L, Wood JR, et al. Calcium and colorectal epithelial cell proliferation in sporadic adenoma patients: a randomized, double-blinded, placebo-controlled clinical trial. *J Natl Cancer Inst* 1995;87:1307–1315.
58. Chen GC, Pang Z, Liu QF. Magnesium intake and risk of colorectal cancer: a meta-analysis of prospective studies. *Eur J Clin Nutr* 2012;66:1182–1186.
59. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *J Clin Oncol* 2011;29:3775–3782.
60. Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*. Washington, DC: National Academies Press; 2011.
61. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. *J Clin Oncol* 2006;24:3527–3534.

62. Campbell PT, Patel AV, Newton CC, et al. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. *J Clin Oncol* 2013;31:876–885.
63. Seitz HK, Simanowski UA, Garzon FT, et al. Possible role of acetaldehyde in ethanol-related rectal cocarcinogenesis in the rat. *Gastroenterology* 1990;98:406–413.
64. Gong J, Hutter C, Baron JA, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. *Cancer Epidemiol Biomarkers Prev* 2012;21:1974–1985.
65. Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *Am J Gastroenterol* 2011;106:1911–1921, quiz 1922.
66. Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. *Dig Dis Sci* 2012;57:1576–1585.
67. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. *N Engl J Med* 1995;333:609–614.
68. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991;325:1593–1596.
69. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. *Cancer* 1998;82:2326–2333.
70. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* 2010;376:1741–1750.
71. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. *N Engl J Med* 2012;367:1596–1606.
72. Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. *J Clin Oncol* 2013;31:4297–4305.
73. Singh S, Singh AG, Murad MH, et al. Bisphosphonates are associated with reduced risk of colorectal cancer: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2013;11:232–239.e1.
74. Toriola AT, Cheng TY, Neuhauser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. *Int J Cancer* 2013;132:2648–2658.
75. Aleksandrova K, Boeing H, Jenab M, et al. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. *Cancer Res* 2012;72:5328–5337.
76. Chi F, Wu R, Zeng YC, et al. Circulation insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis. *Mol Biol Rep* 2013;40:3583–3590.
77. Chen L, Li L, Wang Y, et al. Circulating C-peptide level is a predictive factor for colorectal neoplasia: evidence from the meta-analysis of prospective studies. *Cancer Causes Control* 2013;24:1837–1847.
78. Damin DC, Ziegelmann PK, Damin AP. Human papillomavirus infection and colorectal cancer risk: a meta-analysis. *Colorectal Dis* 2013;15:e420–e428.
79. Rustgi AK. Hereditary gastrointestinal polyposis and nonpolyposis syndromes. *N Engl J Med* 1994;331:1694–1702.
80. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. *N Engl J Med* 1995;332:839–847.
81. Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. *Cell* 1993;75:951–957.
82. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. *N Engl J Med* 1993;329:1982–1987.
83. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. *JAMA* 1997;277:1467–1474.
84. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. *Ann Intern Med* 2003;138:560–570.
85. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. *J Natl Cancer Inst* 1995;87:1114–1125.
86. Weber TK, Conlon W, Petrelli NJ, et al. Genomic DNA-based hMSH2 and hMLH1 mutation screening in 32 Eastern United States hereditary nonpolyposis colorectal cancer pedigrees. *Cancer Res* 1997;57:3798–3803.
87. Burt RW. Familial risk and colorectal cancer. *Gastroenterol Clin North Am* 1996;25:793–803.
88. Garcia-Ruiz A, Milsom JW, Ludwig KA, et al. Right colonic arterial anatomy. Implications for laparoscopic surgery. *Dis Colon Rectum* 1996;39:906–911.
89. Chen Y, Liu ZY, Li RX, et al. Structural studies of initial lymphatics adjacent to gastric and colonic malignant neoplasms. *Lymphology* 1999;32:70–74.
90. Colquhoun PH, Wexner SD. Surgical management of colon cancer. *Curr Gastroenterol Rep* 2002;4:414–419.
91. Shatari T, Fujita M, Nozawa K, et al. Vascular anatomy for right colon lymphadenectomy. *Surg Radiol Anat* 2003;25:86–88.
92. Stein W, Farina A, Gaffney K, et al. Characteristics of colon cancer at time of presentation. *Fam Pract Res J* 1993;13:355–363.
93. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. *Am J Gastroenterol* 1999;94:3039–3045.
94. Rocklin MS, Senagore AJ, Talbot TM. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. *Dis Colon Rectum* 1991;34:794–797.
95. Stotland BR, Siegelman ES, Morris JB, et al. Preoperative and postoperative imaging for colorectal cancer. *Hematol Oncol Clin North Am* 1997;11:635–654.
96. Nollau P, Moser C, Weinland G, et al. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. *Int J Cancer* 1996;66:332–336.
97. Eguchi S, Kohara N, Komuta K, et al. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. *Cancer* 1996;77:1707–1710.
98. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. *Clin Gastroenterol Hepatol* 2013;11:1313–1318.
99. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N Engl J Med* 2003;349:2191–2200.
100. de Haan MC, van Gelder RE, Graser A, et al. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. *Eur Radiol* 2011;21:1747–1763.
101. Pickhardt PJ, Hassan C, Halligan S, et al. Colorectal cancer: CT colonography and colonoscopy for detection—systematic review and meta-analysis. *Radiology* 2011;259:393–405.
102. Sweet A, Lee D, Gairy K, et al. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes. *Appl Health Econ Health Policy* 2011;9:51–64.
103. Boone D, Halligan S, Taylor SA. Evidence review and status update on computed tomography colonography. *Curr Gastroenterol Rep* 2011;13:486–494.
104. Flor N, Mezzananza M, Rigamonti P, et al. Contrast-enhanced computed tomography colonography in preoperative distinction between T1-T2 and T3-T4 staging of colon cancer. *Acad Radiol* 2013;20:590–595.
105. Compton CC. Surgical pathology of colorectal cancer. In Saltz LB, ed. *Colorectal Cancer: Multimodality Management*. Totowa, NJ: Humana Press; 2002: 247–265.
106. Edge SB, Byrd DR, Compton CC, et al., eds. *AJCC Cancer Staging Manual*. 7th ed. Berlin: Springer; 2010.
107. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) rectal cancer: An analysis of 5,988 patients. In: American Society of Clinical Oncology. *Thirty-Ninth Annual Meeting of the ASCO*. Chicago, IL: American Society of Clinical Oncology; 2003.
108. Hari DM, Leung AM, Lee JH, et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? *J Am Coll Surg* 2013;217:181–190.
109. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. *Arch Pathol Lab Med* 2000;124:979–994.
110. Ratto C, Sofo L, Ippoliti M, et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. *Dis Colon Rectum* 1999;42:143–154, discussion 154–158.
111. Wong JH, Severino R, Honnabier MB, et al. Number of nodes examined and staging accuracy in colorectal carcinoma. *J Clin Oncol* 1999;17:2896–2900.
112. Belt EJ, te Velde EA, Krijgsman O, et al. High lymph node yield is related to microsatellite instability in colon cancer. *Ann Surg Oncol* 2012;19:1222–1230.
113. Kuo YH, Lee KF, Chin CC, et al. Does body mass index impact the number of LNs harvested and influence long-term survival rate in patients with stage III colon cancer? *Int J Colorectal Dis* 2012;27:1625–1635.
114. Morikawa T, Tanaka N, Kuchiba A, et al. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. *Arch Surg* 2012;147:715–723.
115. Joseph NE, Sigurdson ER, Hanson AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. *Ann Surg Oncol* 2003;10:213–218.
116. Lykke J, Roikjaer O, Jess P, et al. The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study. *Colorectal Dis* 2013;15:559–565.
117. Greenberg R, Itah R, China R, et al. Metastatic lymph node ratio (LNR) as a prognostic variable in colorectal cancer patients undergoing laparoscopic resection. *Tech Coloproctol* 2011;15:273–279.
118. Moug SJ, McColl G, Lloyd SM, et al. Comparison of positive lymph node ratio with an inflammation-based prognostic score in colorectal cancer. *Br J Surg* 2011;98:282–286.
119. Hong KD, Lee SI, Moon HY. Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer. *J Surg Oncol* 2011;103:406–410.
120. Gao P, Song YX, Wang ZN, et al. Integrated ratio of metastatic to examined lymph nodes and number of metastatic lymph nodes into the AJCC staging system for colon cancer. *PLoS One* 2012;7:e35021.
121. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. *N Engl J Med* 1998;339:223–228.
122. Liefers GJ, Tollenaar RA, Cleton-Jansen AM. Molecular detection of minimal residual disease in colorectal and breast cancer. *Histopathology* 1999;34:385–390.
123. Sirop S, Kanaan M, Korant A, et al. Detection and prognostic impact of micrometastasis in colorectal cancer. *J Surg Oncol* 2011;103:534–537.
124. Jeffers MD, O'Dowd GM, Mulcahy H, et al. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. *J Pathol* 1994;172:183–187.
125. Faerden AE, Sjo OH, Bukholm IR, et al. Lymph node micrometastases and isolated tumor cells influence survival in stage I and II colon cancer. *Dis Colon Rectum* 2011;54:200–206.

126. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. *Arch Surg* 1992;127:392–399.
127. Canavese G, Gipponi M, Catturich A, et al. Sentinel lymph node mapping in early-stage breast cancer: technical issues and results with vital blue dye mapping and radioguided surgery. *J Surg Oncol* 2000;74:61–68.
128. Saha S, Wiese D, Badin J, et al. Technical details of sentinel lymph node mapping in colorectal cancer and its impact on staging. *Ann Surg Oncol* 2000;7:120–124.
129. Paramo JC, Summerall J, Poppiti R, et al. Validation of sentinel node mapping in patients with colon cancer. *Ann Surg Oncol* 2002;9:550–554.
130. Turner RR, Nora DT, Trocha SD, et al. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. *Arch Pathol Lab Med* 2003;127:673–679.
131. Viehl CT, Guller U, Cecini R, et al. Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer: results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. *Ann Surg Oncol* 2012;19:1959–1965.
132. Saha S, Johnston J, Korant A, et al. Aberrant drainage of sentinel lymph nodes in colon cancer and its impact on staging and extent of operation. *Am J Surg* 2013;205:302–305, discussion 305–306.
133. Warner EE, Evans SR. The sentinel node biopsy and colon cancer revisited. *Cancer J* 2002;8:435–437.
134. Cusack JC, Giacco GG, Cleary K, et al. Survival factors in 186 patients younger than 40 years old with colorectal adenocarcinoma. *J Am Coll Surg* 1996;183:105–112.
135. Messerini L, Palomba A, Zampi G. Primary signet-ring cell carcinoma of the colon and rectum. *Dis Colon Rectum* 1995;38:1189–1192.
136. de Bruine AP, Wiggers T, Beek C, et al. Endocrine cells in colorectal adenocarcinomas: incidence, hormone profile and prognostic relevance. *Int J Cancer* 1993;54:765–771.
137. Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. *Hum Pathol* 1999;30:843–848.
138. de la Chapelle A. Microsatellite instability. *N Engl J Med* 2003;349:209–210.
139. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–5257.
140. Boland CR, Sato J, Saito K, et al. Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. *Cancer Detect Prev* 1998;22:377–382.
141. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. *Science* 1993;260:816–819.
142. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. *Gut* 1998;42:673–679.
143. Jass JR. Diagnosis of hereditary non-polyposis colorectal cancer. *Histopathology* 1998;32:491–497.
144. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med* 2000;342:69–77.
145. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. *N Engl J Med* 2001;344:1196–1206.
146. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. *Gastroenterology* 1999;117:123–131.
147. Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. *J Clin Oncol* 2013;31:3664–3672.
148. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. *Clin Cancer Res* 2012;18:890–900.
149. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. *J Natl Cancer Inst* 2013;105:1151–1156.
150. Douillard JY, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013;369:1023–1034.
151. Fearon E, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. *Science* 1990;247:49–56.
152. Mehlen P, Rabizadeh S, Snipas SJ, et al. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. *Nature* 1998;395:801–804.
153. Chiang SF, Hung HY, Tang R, et al. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? *Int J Colorectal Dis* 2012;27:1347–1357.
154. Mallappa S, Sinha A, Gupta S, et al. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. *Colorectal Dis* 2013;15:323–328.
155. Harrison LE, Guillem JG, Paty P, et al. Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. *J Am Coll Surg* 1997;185:55–59.
156. Wolmark N, Fisher B, Wieand HS. The prognostic value of the modifications of the Dukes' C class of colorectal cancer. An analysis of the NSABP clinical trials. *Ann Surg* 1986;203:115–122.
157. Weiss JM, Pflau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results—Medicare data. *J Clin Oncol* 2011;29:4401–4409.
158. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. *J Clin Oncol* 2003;21:433–440.
159. Sinicrope FA, Foster NR, Yothers G, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. *Cancer* 2013;119:1528–1536.
160. Alipour S, Kennecke HF, Woods R, et al. Body mass index and body surface area and their associations with outcomes in stage II and III colon cancer. *J Gastrointest Cancer* 2013;44:203–210.
161. Dehal AN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. *J Clin Oncol* 2012;30:53–59.
162. van de Poll-Franse LV, Haak HR, Coebergh JW, et al. Disease-specific mortality among stage I–III colorectal cancer patients with diabetes: a large population-based analysis. *Diabetologia* 2012;55:2163–2172.
163. Cheung WY, Shi Q, O'Connell M, et al. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. *Clin Colorectal Cancer* 2013;12:179–187.
164. Phipps AI, Shi Q, Newcomb PA, et al. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. *J Clin Oncol* 2013;31:2016–2023.
165. Donohue J, Williams S, Cha S, et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. *J Clin Oncol* 1995;13:1671–1678.
166. Leichman CG, Lens HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. *J Clin Oncol* 1997;15:3223–3229.
167. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. *Cancer Res* 1998;58:1149–1158.
168. Hong L, Han Y, Zhang H, et al. High expression of epidermal growth factor receptor might predict poor survival in patients with colon cancer: a meta-analysis. *Genet Test Mol Biomarkers* 2013;17:348–351.
169. Innocenti F, Undevia SD, Iver L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol* 2004;22:1382–1388.
170. McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response. *Expert Rev Anticancer Ther* 2002;2:113–119.
171. Winawer SJ. Follow-up after polypectomy. *World J Surg* 1991;15:25–28.
172. Lee MG, Hanchard B. Management of colonic polyps by colonoscopic polypectomy. *West Indian Med J* 1991;40:81–85.
173. National Comprehensive Cancer Network Guidelines for Colon Cancer, Version 3.2011. www.nccn.org.
174. Huang EH, Forde KA. Surgical implications of colonoscopy. *Semin Laparosc Surg* 2003;10:13–18.
175. Libutti SK, Forde KA. Surgical considerations III: bowel anastomosis. In Cohen A, Winawer S, eds. *Cancer of the Colon, Rectum and Anus*. New York McGraw Hill; 1995: 445–456.
176. Guenaga KF, Matos D, Willie Jorgensen P, et al. Mechanical bowel preparation for elective colorectal surgery. *Cochrane Database Syst Rev* 2011;(2): CD001544.
177. Makino M, Hisamitsu K, Sugamura K, et al. Randomized comparison of two preoperative methods for preparation of the colon: oral administration of a solution of polyethylene glycol plus electrolytes and total parenteral nutrition. *Hepatogastroenterology* 1998;45:90–94.
178. Chen CF, Lin JK, Leu SY, et al. Evaluation of rapid colon preparation with Golytely. *Zhonghua Yi Xue Za Zhi (Taipei)* 1989;44:45–56.
179. Lewis RT, Goodall RG, Marien B, et al. Is neomycin necessary for bowel preparation in surgery of the colon? Oral neomycin plus erythromycin versus erythromycin-metronidazole. *Can J Surg* 1989;32:265–270.
180. Ram E, Sherman Y, Weil R, et al. Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study. *Arch Surg* 2005;140:285–288.
181. Jung B, Lannerstad O, Pahlman L, et al. Preoperative mechanical preparation of the colon: the patient's experience. *BMC Surg* 2007;7:5.
182. Matsuda A, Kishi T, Musso G, et al. The effect of intraoperative rectal wash-out on local recurrence after rectal cancer surgery: a meta-analysis. *Ann Surg Oncol* 2013;20:856–863.
183. Benson AB 3rd, Choti MA, Cohen AM, et al. NCCN Practice Guidelines for Colorectal Cancer. *Oncology (Williston Park)* 2000;14:203–212.
184. McGinnis LS. Surgical treatment options for colorectal cancer. *Cancer* 1994;74:2147–2150.
185. Garcia-Olmo D, Ontanon J, Garcia-Olmo DC, et al. Experimental evidence does not support use of the "no-touch" isolation technique in colorectal cancer. *Dis Colon Rectum* 1999;42:1449–1456, discussion 1454–1456.

186. Regimbeau JM, Panis Y, Pocard M, et al. Handsewn ileal pouch-anal anastomosis on the dentate line after total proctectomy: technique to avoid incomplete mucosectomy and the need for long-term follow-up of the anal transition zone. *Dis Colon Rectum* 2001;44:43–50, discussion 50–51.
187. Young CJ, Solomon MJ, Eyers AA, et al. Evolution of the pelvic pouch procedure at one institution: the first 100 cases. *Aust N Z J Surg* 1999;69:438–442.
188. Poppen B, Svenberg T, Bark T, et al. Colectomy-proctomucosectomy with S-pouch: operative procedures, complications, and functional outcome in 69 consecutive patients. *Dis Colon Rectum* 1992;35:40–47.
189. Khot UP, Lang AW, Murali K, et al. Systematic review of the efficacy and safety of colorectal stents. *Br J Surg* 2002;89:1096–1102.
190. Sebastian S, Johnston S, Geoghegan T, et al. Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction. *Am J Gastroenterol* 2004;99:2051–2057.
191. Inaba Y, Arai Y, Yamaura H, et al. Phase II clinical study on stent therapy for unresectable malignant colorectal obstruction (JIVROSG-0206). *Am J Clin Oncol* 2012;35:73–76.
192. Lee HJ, Hong SP, Cheon JH, et al. Long-term outcome of palliative therapy for malignant colorectal obstruction in patients with unresectable metastatic colorectal cancers: endoscopic stenting versus surgery. *Gastrointest Endosc* 2011;73:535–542.
193. Branger F, Thibaudeau E, Mucci-Hennekinne S, et al. Management of acute malignant large-bowel obstruction with self-expanding metal stent. *Int J Colorectal Dis* 2010;25:1481–1485.
194. White SI, Abdool SI, Frenkel B, et al. Management of malignant left-sided large bowel obstruction: a comparison between colonic stents and surgery. *ANZ J Surg* 2011;81:257–260.
195. Cheung HY, Chung CC, Tsang WW, et al. Endoscopic approach vs conventional open surgery in the treatment of obstructing left-sided colon cancer: a randomized controlled trial. *Arch Surg* 2009;144:1127–1132.
196. Pirllet IA, Slim K, Kwiatkowski F, et al. Emergency preoperative stenting versus surgery for acute left-sided malignant colonic obstruction: a multicenter randomized controlled trial. *Surg Endosc* 2011;25:1814–1821.
197. van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicenter randomised trial. *Lancet Oncol* 2011;12:344–352.
198. Sabbagh C, Brower F, Diouf M, et al. Is stenting as “a bridge to surgery” an oncologically safe strategy for the management of acute, left-sided, malignant, colonic obstruction? A comparative study with a propensity score analysis. *Ann Surg* 2013;258:107–115.
199. Lichten JB, Reid JJ, Zahalsky MP, et al. Laparoscopic cholecystectomy in the new millennium. *Surg Endosc* 2001;15:867–872.
200. Theodoridis TD, Bonitis JN. Laparoscopy and oncology: where do we stand today? *Ann N Y Acad Sci* 2003;997:282–291.
201. Hartley JE, Monson JR. The role of laparoscopy in the multimodality treatment of colorectal cancer. *Surg Clin North Am* 2002;82:1019–1033.
202. Mori T, Abe N, Sugiyama M, et al. Laparoscopic hepatobiliary and pancreatic surgery: an overview. *J Hepatobiliary Pancreat Surg* 2002;9:710–722.
203. Grover AC, Skarulis M, Alexander HR, et al. A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. *Surgery* 2005;138:1003–1008, discussion 1008.
204. Goletti O, Celona G, Monzani F, et al. Laparoscopic treatment of pancreatic insulinoma. *Surg Endosc* 2003;17:1499.
205. Patankar SK, Larach SW, Ferrara A, et al. Prospective comparison of laparoscopic vs. open resections for colorectal adenocarcinoma over a ten-year period. *Dis Colon Rectum* 2003;46:601–611.
206. Delaney CP, Kiran RP, Senagore AJ, et al. Case-matched comparison of clinical and financial outcome after laparoscopic or open colorectal surgery. *Ann Surg* 2003;238:67–72.
207. Feliciotti F, Paganini AM, Guerrieri M, et al. Results of laparoscopic vs open resections for colon cancer in patients with a minimum follow-up of 3 years. *Surg Endosc* 2002;16:1158–1161.
208. Lezoche E, Feliciotti F, Paganini AM, et al. Results of laparoscopic versus open resections for non-early rectal cancer in patients with a minimum follow-up of four years. *HepatoGastroenterology* 2002;49:1185–1190.
209. Cobb WS, Lokey JS, Schwab DP, et al. Hand-assisted laparoscopic colectomy: a single-institution experience. *Am Surg* 2003;69:578–580.
210. Lauter DM, Lau ST, Lanzafame K. Combined laparoscopic-assisted right hemicolectomy and low anterior resection for synchronous colorectal carcinomas. *Surg Endosc* 2003;17:1498.
211. Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. *JAMA* 2002;287:321–328.
212. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. *N Engl J Med* 2004;350:2050–2059.
213. Jayne DG, Guilloit PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol* 2007;25:3061–3068.
214. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. *Br J Surg* 2013;100:75–82.
215. McNally ME, Todd Moore B, Brown KM. Single-incision laparoscopic colectomy for malignant disease. *Surg Endosc* 2011;25:3559–3565.
216. Gash KJ, Goede AC, Chambers W, et al. Laparoscopic single-site surgery is feasible in complex colorectal resections and could enable day case colectomy. *Surg Endosc* 2011;25:835–840.
217. Katsuno G, Fukunaga M, Nagakari K, et al. Single-incision laparoscopic colectomy for colon cancer: early experience with 31 cases. *Dis Colon Rectum* 2011;54:705–710.
218. Chen WT, Chang SC, Chiang HC, et al. Single-incision laparoscopic versus conventional laparoscopic right hemicolectomy: a comparison of short-term surgical results. *Surg Endosc* 2011;25:1887–1892.
219. Yun JA, Yun SH, Park YA, et al. Single-incision laparoscopic right colectomy compared with conventional laparoscopy for malignancy: assessment of perioperative and short-term oncologic outcomes. *Surg Endosc* 2013;27:2122–2130.
220. deSouza AL, Prasad LM, Park JJ, et al. Robotic assistance in right hemicolectomy: is there a role? *Dis Colon Rectum* 2010;53:1000–1006.
221. Luca F, Ghezzi TL, Valvo M, et al. Surgical and pathological outcomes after right hemicolectomy: case-matched study comparing robotic and open surgery. *Int J Med Robot* 2011 [ePub ahead of print].
222. Diana M, Perretta S, Wall J, et al. Transvaginal specimen extraction in colorectal surgery: current state of the art. *Colorectal Dis* 2011;13:e104–e111.
223. Park JS, Choi GS, Kim HJ, et al. Natural orifice specimen extraction versus conventional laparoscopically assisted right hemicolectomy. *Br J Surg* 2011;98:710–715.
224. Rieder E, Spaun GO, Khajanchee YS, et al. A natural orifice transrectal approach for oncologic resection of the rectosigmoid: an experimental study and comparison with conventional laparoscopy. *Surg Endosc* 2011;25:3357–3363.
225. Nivatvongs S. Surgical management of early colorectal cancer. *World J Surg* 2000;24:1052–1055.
226. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. *JAMA* 1988;259:3571–3578.
227. Libutti S, Saltz L, Tepper J. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Principles and Practice of Oncology*. 8th ed. Philadelphia, PA: Lippincott Williams, & Wilkins; 2008:1261–1264.
228. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. *Lancet* 1995;345:939–944.
229. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C0-1. *J Natl Cancer Inst* 1988;80:30–36.
230. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. *J Clin Oncol* 2003;21:2896–2903.
231. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. *J Clin Oncol* 2005;23:8671–8678.
232. Kerr DJ, Gray R, McConkey C, et al. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules — less pain, same gain. QUASAR Colorectal Cancer Study Group. *Ann Oncol* 2000;11:947–955.
233. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. *Lancet* 2000;355:1588–1596.
234. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. *J Clin Oncol* 1998;16:295–300.
235. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005;352:2696–2704.
236. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. *J Clin Oncol* 2006;24:2059–2064.
237. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 2009;27:3109–3116.
238. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. *J Clin Oncol* 2011;29:3768–3774.
239. Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. *Cancer* 2012;118:5614–5622.
240. Uwah AN, Ackler J, Leighton JC Jr, et al. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. *Clin Colorectal Cancer* 2012;11:275–279.
241. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. *J Clin Oncol* 2013;31:2600–2606.

242. Toumigand C, Andre T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. *J Clin Oncol* 2012;30:3353–3360.
243. Benson AB 3rd, Bekali-Saab T, Chan E, et al. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2013;11:519–528.
244. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *J Clin Oncol* 2011;29:1465–1471.
245. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337–345.
246. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000;355:1041–1047.
247. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000;343:905–914.
248. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. *N Engl J Med* 2001;345:144–145, author reply 146.
249. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. *J Clin Oncol* 2007;25:3456–3461.
250. Yehou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). *Ann Oncol* 2009;20:674–680.
251. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. *J Clin Oncol* 2009;27:3117–3125.
252. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). *J Clin Oncol* 2009;27: Abstr 4001.
253. Bertagnoli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. *J Clin Oncol* 2009;27:1814–1821.
254. Allegra CJ, Yothers G, O'Connell MJ, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. *J Clin Oncol* 2013;31:359–364.
255. de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. *Lancet Oncol* 2012;13:1225–1233.
256. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA* 2012;307:1383–1393.
257. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. *J Clin Oncol* 2002;20:3999–4005.
258. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. *J Clin Oncol* 1999;17:1356–1363.
259. McKenzie S, Nelson R, Mailey B, et al. Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. *Cancer* 2011;117:5493–5499.
260. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. *J Clin Oncol* 2011;29:3381–3388.
261. Wu X, Zhang J, He X, et al. Postoperative adjuvant chemotherapy for stage II colorectal cancer: a systematic review of 12 randomized controlled trials. *J Gastrointest Surg* 2012;16:646–655.
262. Ishiguro M, Mochizuki H, Tomita N, et al. Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. *BMC Cancer* 2012;12:281.
263. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. *N Engl J Med* 1994;331:213–221.
264. Elsalh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. *Clin Colorectal Cancer* 2001;1:104–109.
265. Willet CG, Tepper JE, Cohen AM. Obstructive and perforative colonic carcinoma: patterns of failure. *J Clin Oncol* 1985;3:379–384.
266. Sato H, Maeda K, Sugihara K, et al. High-risk stage II colon cancer after curative resection. *J Surg Oncol* 2011;104:45–52.
267. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med* 2003;349:247–257.
268. Kim GP, Colangelo H, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. *J Clin Oncol* 2007;25:767–772.
269. Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. *J Clin Oncol* 2008;26:4008.
270. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. *J Natl Cancer Inst* 2011;103:863–875.
271. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. *J Clin Oncol* 2009;27: Abstr 4000.
272. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. *Br J Cancer* 2009;100:266–273.
273. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* 2010;28:466–474.
274. Ogino S, Noshko K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. *J Clin Oncol* 2009;27:4591–4598.
275. Sharif S, O'Connell MJ. Gene signatures in stage II colon cancer: a clinical review. *Curr Colorectal Cancer Rep* 2012;8:225–231.
276. Hornberger J, Lyman GH, Chien R, et al. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. *Value Health* 2012;15:1014–1021.
277. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. *Ann Surg* 2013;257:1053–1058.
278. Kennedy RD, Bylesjo M, Kerr P, et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. *J Clin Oncol* 2011;29:4620–4626.
279. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol* 2004;22:3408–3419.
280. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. *Eur J Cancer* 2010;46:1049–1055.
281. Czaykowski PM, Gill S, Kennecke HF, et al. Adjuvant chemotherapy for stage III colon cancer: does timing matter? *Dis Colon Rectum* 2011;54:1082–1089.
282. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. *J Clin Oncol* 1990;8:1466–1475.
283. Long term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). *Lancet* 1995;345:349–352.
284. Weber W, Laffer U, Metzger U. Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. *Anticancer Res* 1993;13:1839–1840.
285. Kelsen DP, Saltz L, Cohen AM, et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. *Cancer* 1994;74:2224–2233.
286. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. *Br J Cancer* 1998;77:1349–1354.
287. Sammartino P, Sibio S, Biacchi D, et al. Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. *Gastroenterol Res Pract* 2012;2012:141585.
288. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. *Cancer Prev Res (Phila)* 2013;6:18–26.
289. Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. *Lancet Oncol* 2012;13:1152–1160.
290. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. *Ann Intern Med* 1995;123:904–910.
291. Burt RW. Colon cancer screening. *Gastroenterology* 2000;119:837–853.
292. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med* 1993;328:1365–1371.
293. Graham RA, Wang S, Catalano PJ, et al. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. *Ann Surg* 1998;228:59–63.

294. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. *JAMA* 1997;277:915-919.
295. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. *N Engl J Med* 1992;326:658-662.
296. Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol* 2013;31:4465-4470.
297. Bruinvels DJ, Stiggelbout AM, Lievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. *Ann Surg* 1994;219:174-182.
298. Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. *Dis Colon Rectum* 1993;36:1063-1068.
299. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. *J Clin Oncol* 1996;14:2843-2877.
300. Martin EW Jr, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. *Ann Surg* 1985;202:310-317.
301. Balz JB, Martin EW, Minton JP. CEA as an early indicator for second-look procedure in colorectal carcinoma. *Rev Surg* 1977;34:1-4.
302. Bruinvels DJ, de Brauw LM, Lievit J, et al. Attitudes towards detection and management of hepatic metastases of colorectal origin: a second look. *HPB Surg* 1994;8:115-122.
303. Libutti SK, Alexander HR Jr, Choyke P, et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. *Ann Surg Oncol* 2001;8:779-786.
304. Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. *Cancer* 1974;34:1278-1292.
305. Ito K, Hibi K, Ando H, et al. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. *Jpn J Clin Oncol* 2002;32:54-58.
306. Takenoshita S, Hashizume T, Asao T, et al. Immunoscintigraphy using 99mTc-labeled anti-CEA monoclonal antibody for patients with colorectal cancer. *Anticancer Res* 1995;15:471-475.
307. Moffat FL Jr, Pinsky CM, Hammershaib L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. *J Clin Oncol* 1996;14:2295-2305.
308. Beatty JD, Hyams DM, Morton BA, et al. Impact of radiolabeled antibody imaging on management of colon cancer. *Am J Surg* 1989;157:13-19.
309. Swanson RS. Is an FDG-PET scan the new imaging standard for colon cancer? *Ann Surg Oncol* 2001;8:752-753.
310. Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. *J Clin Oncol* 2005;23:8512-8519.
311. Schoemaker D, Black R, Giles L, et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. *Gastroenterology* 1998;114:7-14.
312. Makela J, Laitinen S, Kairaluoma MI. Early results of follow-up after radical resection for colorectal cancer. Preliminary results of a prospective randomized trial. *Surg Oncol* 1992;1:157-161.
313. Ohlsson B, Breland U, Ekberg H, et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. *Dis Colon Rectum* 1995;38:619-626.
314. Benson AB 3rd, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. *J Clin Oncol* 2000;18:3586-3588.
315. Inadomi JM, Sonnenberg A. The impact of colorectal cancer screening on life expectancy. *Gastrointest Endosc* 2000;51:517-523.
316. Fornasari M, Valentini M, Poletti M, et al. Evaluation of the risk for metachronous colorectal neoplasms following intestinal polypectomy: a clinical, endoscopic and pathological study. *Hepatogastroenterology* 1998;45:1565-1572.
317. Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. *BMJ* 2002;324:813.
318. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. *J Clin Oncol* 2004;22:3475-3484.
319. Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. *J Clin Oncol* 2009;27:3379-3384.
320. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. *J Clin Oncol* 2012;30:3223-3228.
321. Stillwell AP, Buettner PG, Siu SK, et al. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. *Dis Colon Rectum* 2011;54:535-544.
322. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumor inhibitory compounds. *Nature* 1957;179:663-666.
323. Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. *J Clin Oncol* 1996;14:2274-2279.
324. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. *J Clin Oncol* 1989;7:425-432.
325. Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. *J Clin Oncol* 1998;16:418-426.
326. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. *Cancer Chemother Pharmacol* 2000;45:291-297.
327. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. *J Clin Oncol* 2000;18:1337-1345.
328. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001;19:2282-2292.
329. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* 2001;19:4097-4106.
330. Pizzolato JF, Saltz LB. The camptothecins. *Lancet* 2003;361:2235-2242.
331. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. *Cancer Res* 1991;51:4187-4191.
332. Saltz L, Kanowitz J, Kemeny NE, et al. A phase I clinical and pharmacologic trial of irinotecan, 5-fluorouracil, and leucovorin in patients with advanced solid tumors. *J Clin Oncol* 1996;14:2959-2967.
333. Andre T, Louvet C, Maindtraut-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *GERCOR. Eur J Cancer* 1999;35:1343-1347.
334. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. *J Clin Oncol* 2007;25:4779-4786.
335. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. *Cancer Chemother Pharmacol* 1990;25:299-303.
336. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. *Ann Oncol* 1998;9:1053-1071.
337. Libutti S, Saltz L, Tepper J. Cancer of the colon. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Principles and Practice of Oncology*. 9th ed. Philadelphia, PA: Lippincott Williams, & Wilkins; 2011:1266-1268.
338. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2000;18:136-147.
339. Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. *J Clin Oncol* 1996;14:2950-2958.
340. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. *Lancet* 1997;350:681-686.
341. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. *J Clin Oncol* 1997;15:808-815.
342. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. *J Clin Oncol* 1999;17:3560-3568.
343. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. *Eur J Cancer* 1997;33:214-219.
344. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. *J Clin Oncol* 2009;27: Abstr LBA4.
345. Moehler M, Hoffman T, Hildner K, et al. Weekly oxaliplatin, high-dose folic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic

- colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. *Z Gastroenterol* 2002;40:957–964.
346. de Gramont A, Figuer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000;18:2938–2947.
 347. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. *J Clin Oncol* 2003;21:2059–2069.
 348. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). *GERCOR. Eur J Cancer* 1999;35:1338–1342.
 349. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004;22:229–237.
 350. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study. *J Clin Oncol* 2013;31:Abstr 3501.
 351. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Grupo Oncologico Italia Meridionale. *J Clin Oncol* 2005;23:4866–4875.
 352. Goldberg RM. N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer. *Clin Colorectal Cancer* 2002;2:81.
 353. Miller L, Emanuel D, Elfring G, et al. 60-day, all-cause mortality with first-line irinotecan/ fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCR). *Proc Am Soc Clin Oncol* 2002;21:129a.
 354. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004;22:23–30.
 355. Tournigand C, Cervantes A, Figuer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. *J Clin Oncol* 2006;24:394–400.
 356. de Gramont A, Buyse M, Abrahamson JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. *J Clin Oncol* 2007;25:3224–3229.
 357. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. *J Clin Oncol* 2006;24:Abstr 3510.
 358. Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. *J Clin Oncol* 2003;21:2703–2707.
 359. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol* 2007;25:1670–1676.
 360. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *J Clin Oncol* 2008;26:2006–2012.
 361. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. *Lancet* 2003;361:457–464.
 362. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. *J Clin Oncol* 2009;27:5727–5733.
 363. Perez-Staub N, Chibaudel B, Figuer A, et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. *J Clin Oncol* 2008;26:Abstr 4037.
 364. Yeoh C, Chau I, Cunningham D, et al. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. *Clin Colorectal Cancer* 2003;3:102–107.
 365. Lal KR, et al. A phase II, randomized, multicentre, trial of irinotecan until disease progression (PD) versus 8 cycles, in advanced colorectal cancer (CRC) resistant to fluoropyrimidines. In: *American Society of Clinical Oncology Annual Meeting*. Chicago, IL: American Society of Clinical Oncology; 2003.
 366. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet* 2007;370:135–142.
 367. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet* 2007;370:143–152.
 368. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004;3:391–400.
 369. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev* 2004;25:581–611.
 370. Kabbinnar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 2003;21:60–65.
 371. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–2342.
 372. Kabbinnar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol* 2005;23:3706–3712.
 373. Seymour MT. Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC). *Proc Am Soc Clin Oncol* 2005;23:Abstr 3518. http://www.asco.org/ac/1,1003_12-002511-00_18-0034-00_19-001999,00.asp.
 374. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol* 2007;25:1539–1544.
 375. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008;26:2013–2019.
 376. Skillings JA, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. *J Clin Oncol* 2005;23:3019.
 377. Ganapathi AM, Westmoreland T, Tyler D, et al. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. *J Am Coll Surg* 2012;214:582–588, discussion 588–590.
 378. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol* 2013;14:29–37.
 379. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol* 2012;30:3499–3506.
 380. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013;381:303–312.
 381. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin Cancer Res* 2001;7:2958–2970.
 382. Real FX, Rettig WJ, Chesna PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. *Cancer Res* 1986;46:4726–4731.
 383. Carpenter C, Cohen S. Epidermal growth factor. *J Biol Chem* 1990;265:7709–7712.
 384. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. *Cancer Treat Rev* 2004;30:255–268.
 385. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). *J Clin Oncol* 2001;20:Abstr 7.
 386. Saltz LB, Meropol NJ, Poehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *J Clin Oncol* 2004;22:1201–1208.
 387. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. *N Engl J Med* 2007;357:2040–2048.
 388. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. *Ann Oncol* 2008;19:92–98.
 389. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. *Cancer* 2007;110:980–988.
 390. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *J Clin Oncol* 2007;25:1658–1664.
 391. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* 2008;26:374–379.
 392. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. *J Clin Oncol* 2007;25:3230–3237.
 393. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:1626–1634.

394. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757–1765.
395. Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. *J Clin Oncol* 2012;30:3570–3577.
396. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010;11:753–762.
397. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol* 2009;27:2091–2096.
398. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol* 2012;30:2956–2962.
399. Lin YL, Liao JY, Yu SC, et al. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. *PLoS One* 2012;7:e50701.
400. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–1417.
401. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011;29:2011–2019.
402. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27:663–671.
403. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011;377:2103–2114.
404. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. *J Clin Oncol* 2012;30:1755–1762.
405. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010;28:4697–4705.
406. Peeters M, Price T, Hotko Y, et al. 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). *EJC Supplements* 2009;7:10.
407. Venook AP, Niedzwiecki D, Heinz-Josef L, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). *J Clin Oncol* 2014;35(suppl; abstr LBA3):5s.
408. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. *J Clin Oncol* 2007;25:5390–5396.
409. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? *J Clin Oncol* 2005;23:5235–5246.
410. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. *J Clin Oncol* 2007;25:3644–3648.
411. Chung CH, Mirakhor B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. *N Engl J Med* 2008;358:1109–1117.
412. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. *J Natl Cancer Inst* 2005;97:1221–1224.
413. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. *J Clin Oncol* 2004;22:3510.
414. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *J Clin Oncol* 2005;23:1803–1810.
415. Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. *Clin Cancer Res* 2010;16:2205–2213.
416. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. *J Clin Oncol* 2007;25:4557–4561.
417. Segal NH, Reidy-Lagunes D, Capanu M, et al. Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). *J Clin Oncol* 2009;27:Abstr 4087.
418. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 2009;360:563–572.
419. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase III trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 2009;27:672–680.
420. Oza A, Townsley C, Siu L, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. *Proc Am Soc Clin Oncol* 2003;785:50.
421. Dorigschaw O, et al. ZD 1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). *Proc Am Soc Clin Oncol* 2003;22.
422. Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. *J Clin Oncol* 2007;25:4793–4799.
423. Blanke CD. Celecoxib with chemotherapy in colorectal cancer. *Oncology (Huntingt)* 2002;16:17–21.
424. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. *JAMA* 2009;302:649–658.
425. Ali R, Toh HC, Chia WK, et al. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer—the ASCOLT study: study protocol for a randomized controlled trial. *Trials* 2011;12:261.
426. Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. *Br J Cancer* 2012;106:1564–1570.
427. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. *J Clin Oncol* 2004;22:3631–3638.
428. Metzger R, Danenberg K, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. *Clin Cancer Res* 1998;4:2371–2376.
429. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. *Clin Cancer Res* 2000;6:1322–1327.
430. Iqbal S, Lenz HJ. Targeted therapy and pharmacogenomic programs. *Cancer* 2003;97:2076–2082.
431. Ebert MP, Tanzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. *N Engl J Med* 2012;366:44–53.